[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597324":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":31,"centralContacts":39,"locations":50,"responsibleParty":71,"collaborators":44,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":44,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":44,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":44,"overallStatus":95,"whyStopped":44,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"South Valley University","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A (Drug Comination Therapy)","ACTIVE_COMPARATOR","Twenty patients with premature ejaculation , matching inclusion \\& exclusion criteria as mentioned before, will receive SSRI (paroxetine 20mg\u002Fday) + PDE5 inhibitor (sildenafil 25mg\u002Fday) for 3 months . Follow up clinically every 4 weeks for 12 weeks.",[13],"Drug: Paroxetine 20 Mg Oral Tablet",{"label":15,"type":10,"description":16,"interventionNames":17},"Group B (Monotherapy)","Twenty patients with premature ejaculation will receive SSRI (paroxetine 20mg\u002Fday) + placebo for 3 months . Follow up clinically every 4 weeks for 12 weeks.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Group C (Control)","Twenty healthy matched individuals will receive placebo + placebo for 3 months . Follow up clinically every 4 weeks for 12 weeks.",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Paroxetine 20 Mg Oral Tablet","to compare the safety and efficacy of paroxetine alone versus the combination of paroxetine and sildenafil in Premature Ejaculation Patients with genetic polymorphism in the serotonin transporter gene-linked polymorphic region.",[9,15,19],[29,30],"sildenafil 25mg Oral Tablet","Placebo",[32,36],{"name":33,"affiliation":34,"role":35},"Mostafa Adam Ali El-Taib, Professor","Dermatology, venereology and andrology ,Qena Faculty of medicine ,south valley university.","STUDY_CHAIR",{"name":37,"affiliation":34,"role":38},"Ebtehal Alaa El-Din Kotop Mohamed, Lecturer","STUDY_DIRECTOR",[40,46],{"name":41,"role":42,"phone":43,"phoneExt":44,"email":45},"Mohamed Ahmed Mohamed Mousaa, MSC","CONTACT","+201061574354",null,"drmohamedelmurshedy@gmail.com",{"name":47,"role":42,"phone":48,"phoneExt":44,"email":49},"Mohammed Hosny Hassan., professor","+201098473605","mohammedhosnyhassaan@med.svu.edu.eg",[51],{"facility":52,"status":44,"city":53,"state":44,"zip":44,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"South Valley University Hospital","Qina","Egypt","EG",{"type":57,"coordinates":58},"Point",[59,60],32.72671,26.16418,{"lat":60,"lon":59},[63,67],{"name":64,"role":42,"phone":65,"phoneExt":44,"email":66},"Eisa Mohammed Hegazy, Professor","+201094337795","eisa_mohamed4152@med.svu.edu.eg",{"name":68,"role":42,"phone":69,"phoneExt":44,"email":70},"Soheir Abdel-Hamid Ali, Lecturer","+201066877343","Soher.abdel-hamed@med.svu.edu.eg",{"type":72,"investigatorFullName":73,"investigatorTitle":74,"investigatorAffiliation":5,"oldNameTitle":44,"oldOrganization":44},"PRINCIPAL_INVESTIGATOR","Mohamed Ahmed Mohamed","Resident at Dermatology , venereology and andrology, Faculty of medicine","100597324","therapeutic-outcomes-of-selective-serotonin-reuptake-inhibitors-and-phosphodiesterase-5-inhibitors-combination-therapy-versus-monotherapy-100597324",false,"NCT07057011","Therapeutic Outcomes of Selective Serotonin Reuptake Inhibitors and Phosphodiesterase-5 Inhibitors Combination Therapy Versus Monotherapy","Therapeutic Outcomes of Selective Serotonin Reuptake Inhibitors and Phosphodiesterase-5 Inhibitors Combination Therapy Versus Monotherapy in Premature Ejaculation Patients With the Serotonin Transporter Gene Polymorphism (SLC6A4)","Inclusion Criteria:\n\n* Patients with PE: Men aged 18-60 years with a diagnosis of PE according to the International Society for Sexual Medicine (ISSM) criteria.\n* Healthy controls: Men aged 18-60 years without a history of PE or other sexual dysfunctions.\n\nExclusion Criteria:\n\n* Other sexual dysfunctions: Erectile dysfunction, delayed ejaculation, or other sexual disorders.\n* Cardiovascular disease: history of cardiovascular disease, hypertension, or stroke.\n* Neurological or psychiatric disorders: Conditions that may affect sexual function, such as depression, anxiety, or Parkinson's disease.\n* Medications affecting sexual function: Current use of medications that may impact sexual function, such as antidepressants or antipsychotics.",true,"MALE","18 Years","60 Years",{"count":87,"type":88},60,"ESTIMATED","INTERVENTIONAL",[91],"NA","Premature ejaculation (PE) is a prevalent male sexual dysfunction that affects as many as 20-30% of men regardless of age and ethnicity.The International Society for Sexual Medicine defines premature ejaculation as a male sexual dysfunction characterised by ejaculation that always or nearly always occurs before or within about 1 minute of vaginal penetration from the first sexual experience (lifelong premature ejaculation) or a clinically significant and bothersome reduction in latency time, often to about 3 minutes or less (acquired premature ejaculation), the inability to delay ejaculation on all or nearly all vaginal penetrations and with negative personal consequences include distress, bother, frustration, and avoidance of sexual intimacy.",[94],"Premature Ejaculation","NOT_YET_RECRUITING","2025-07-06",{"date":98,"type":99},"2025-07-09","ACTUAL",{"date":101,"type":88},"2025-07-01",{"date":103,"type":88},"2026-02-10",{"name":5,"class":6},1]